NASDAQ · Financial Statements

Molecular Partners AG (MOLN) Financial Statements

$3.91 NASDAQ: MOLN Market Cap $146.67M

Molecular Partners AG most recently reported annual revenue of $0, a net loss of $62.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Molecular Partners AG: Revenue fell from $23.0M in 2016 to $0 in 2025, a change of -100.0% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -84.6% to -1231.7%, a shift of -1147.2 percentage points; the most recent year shows a net loss of $62.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$23.0M$20.0M$10.0M$20.0M$9.0M$9.0M$190.0M$7.0M$5.0M$0
Operating Expenses$43.0M$46.0M$48.0M$57.0M$68.0M$73.0M$73.0M$68.0M$66.0M$58.0M
Operating Profit$-19.0M$-26.0M$-37.0M$-37.0M$-58.0M$-63.0M$117.0M$-61.0M$-61.0M$-58.0M
Operating Margin-84.6%-129.1%-361.3%-179.9%-624.2%-679.7%61.5%-868.3%-1231.7%0.0%
Other Income$1.0M$0$0$0$-4.0M$0$1.0M$-1.0M$7.0M$-4.0M
Interest$0$0$0$0$0$1.0M$1.0M$0$0$0
Depreciation$1.0M$1.0M$1.0M$2.0M$3.0M$3.0M$2.0M$2.0M$2.0M$2.0M
Profit Before Tax$-19.0M$-25.0M$-37.0M$-36.0M$-63.0M$-64.0M$118.0M$-62.0M$-54.0M$-62.0M
Tax$0$0$420,000$-50,000$20,000$0$0$0$0$0
Net Profit$-19.0M$-25.0M$-37.0M$-36.0M$-63.0M$-64.0M$118.0M$-62.0M$-54.0M$-62.0M
EPS$-0.91$-1.22$-1.75$-1.69$-2.51$-2.06$3.54$-1.89$-1.59$-1.65
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue$0$3.0M$1.0M$3.0M$2.0M$1.0M$0$0$0$0$0$0
Operating Expenses$16.0M$16.0M$18.0M$19.0M$18.0M$15.0M$15.0M$18.0M$17.0M$15.0M$16.0M$13.0M
Operating Profit$-16.0M$-13.0M$-17.0M$-16.0M$-16.0M$-15.0M$-15.0M$-18.0M$-17.0M$-15.0M$-16.0M$-13.0M
Operating Margin-3827.2%-530.9%-1613.2%-579.2%-1030.0%-2142.3%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-16.0M$-11.0M$-20.0M$-11.0M$-15.0M$-16.0M$-11.0M$-19.0M$-20.0M$-15.0M$-16.0M$-13.0M
Tax$0$0$0$0$0$0$-20,000$10,000$0$0$-30,000$0
Net Profit$-16.0M$-11.0M$-20.0M$-11.0M$-15.0M$-16.0M$-11.0M$-19.0M$-20.0M$-15.0M$-16.0M$-13.0M
EPS$-0.49$-0.35$-0.60$-0.34$-0.45$-0.49$-0.33$-0.45$-0.55$-0.32$-0.33$-0.35

Over the 10 years reported for Molecular Partners AG, cash stood at $83.0M in the latest year, shareholders' equity was $4.0M, current assets covered current liabilities 8.82 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$184.0M$144.0M$155.0M$105.0M$188.0M$173.0M$262.0M$198.0M$159.0M$102.0M
Current Assets$182.0M$143.0M$153.0M$100.0M$178.0M$164.0M$255.0M$192.0M$154.0M$97.0M
Cash$150.0M$131.0M$99.0M$76.0M$134.0M$72.0M$88.0M$67.0M$64.0M$83.0M
Inventory$0$-9.0M$-2.0M$0$0$0$0$0$0$0
Receivables$1.0M$1.0M$52.0M$3.0M$3.0M$26.0M$2.0M$2.0M$0$2.0M
Fixed Assets$2.0M$2.0M$1.0M$4.0M$9.0M$8.0M$7.0M$6.0M$4.0M$5.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$30.0M$10.0M$0$19.0M$40.0M$61.0M$161.0M$120.0M$86.0M$10.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$48.0M$28.0M$63.0M$51.0M$80.0M$65.0M$27.0M$22.0M$17.0M$22.0M
Current Liabilities$16.0M$14.0M$37.0M$29.0M$58.0M$47.0M$17.0M$14.0M$11.0M$11.0M
Borrowings$0$0$0$3.0M$7.0M$6.0M$5.0M$4.0M$2.0M$4.0M
Other Liabilities$48.0M$28.0M$63.0M$48.0M$73.0M$59.0M$22.0M$18.0M$14.0M$18.0M
Equity$2.0M$2.0M$2.0M$2.0M$3.0M$3.0M$4.0M$4.0M$4.0M$4.0M
Reserves$136.0M$117.0M$92.0M$54.0M$107.0M$107.0M$235.0M$176.0M$142.0M$80.0M

For Molecular Partners AG, operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $52.0M; free cash flow was positive in 1 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-35.0M$-40.0M$-42.0M$-1.0M$-29.0M$-91.0M$119.0M$-59.0M$-59.0M$-51.0M
Investing Cash Flow$-12.0M$20.0M$9.0M$-22.0M$-23.0M$-24.0M$-103.0M$44.0M$40.0M$72.0M
Financing Cash Flow$0$0$0$1.0M$1.0M$0$0$0$-2.0M$0
Net Cash Flow$-46.0M$-18.0M$-32.0M$-23.0M$58.0M$-62.0M$16.0M$-21.0M$-3.0M$19.0M
Free Cash Flow$-36.0M$-41.0M$-43.0M$-3.0M$-31.0M$-92.0M$117.0M$-60.0M$-60.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.32
EV / EBITDA-1.09
FCF Yield-39.55%
Quick Ratio9.42
Interest Coverage-1729.87
Return 1Y9.52%
Return 3Y-40.21%
Return 5Y-78.68%

Molecular Partners AG (MOLN) financials — frequently asked questions

What is Molecular Partners AG's annual revenue?

Molecular Partners AG (MOLN) reported annual revenue of $0 in its most recent fiscal year.

What is Molecular Partners AG's net profit?

Molecular Partners AG (MOLN) reported a net loss of $62.0M in its most recent fiscal year.

What is MOLN EV/EBITDA?

Molecular Partners AG's enterprise value to EBITDA (EV/EBITDA) ratio is -1.09. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
MOLN Overview MOLN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.